OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producingEscherichia coli | Zendy

David M. Livermore | Zendy; Michaela Day | Zendy; Paul Cleary | Zendy; Katie L. Hopkins | Zendy; Mark A. Toleman | Zendy; David W. Wareham | Zendy; Camilla Wiuff | Zendy; Michel Doumith | Zendy; Neil Woodford | Zendy

Open Access

OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producingEscherichia coli

Author(s) -

David M. Livermore,

Michaela Day,

Paul Cleary,

Katie L. Hopkins,

Mark A. Toleman,

David W. Wareham,

Camilla Wiuff,

Michel Doumith,

Neil Woodford

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky453

Subject(s) - microbiology and biotechnology , penicillin , amikacin , piperacillin , escherichia coli , agar dilution , carriage , tazobactam , biology , tobramycin , cephalosporin , beta lactamase , antibiotics , imipenem , minimum inhibitory concentration , gentamicin , medicine , antibiotic resistance , bacteria , gene , genetics , pseudomonas aeruginosa , pathology

ESBL-producing Escherichia coli have expanded globally since the turn of the century and present a major public health issue. Their in vitro susceptibility to penicillin/inhibitor combinations is variable, and clinical use of these combinations against ESBL producers remains controversial. We hypothesized that this variability related to co-production of OXA-1 penicillinase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research